---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2026-02-14T14:18:18.982962'
end_time: '2026-02-14T14:24:50.401769'
duration_seconds: 391.42
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: EGR2
  gene_symbol: EGR2
  uniprot_accession: P11161
  protein_description: 'RecName: Full=E3 SUMO-protein ligase EGR2; EC=2.3.2.- {ECO:0000269|PubMed:21836637};
    AltName: Full=AT591; AltName: Full=E3 SUMO-protein transferase ERG2 {ECO:0000305};
    AltName: Full=Early growth response protein 2; Short=EGR-2; AltName: Full=Zinc
    finger protein Krox-20;'
  gene_info: Name=EGR2; Synonyms=KROX20;
  organism_full: Homo sapiens (Human).
  protein_family: Belongs to the EGR C2H2-type zinc-finger protein family.
  protein_domains: EGR_N. (IPR021849); Znf_C2H2_sf. (IPR036236); Znf_C2H2_type. (IPR013087);
    DUF3446 (PF11928); zf-C2H2 (PF00096)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 15
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** P11161
- **Protein Description:** RecName: Full=E3 SUMO-protein ligase EGR2; EC=2.3.2.- {ECO:0000269|PubMed:21836637}; AltName: Full=AT591; AltName: Full=E3 SUMO-protein transferase ERG2 {ECO:0000305}; AltName: Full=Early growth response protein 2; Short=EGR-2; AltName: Full=Zinc finger protein Krox-20;
- **Gene Information:** Name=EGR2; Synonyms=KROX20;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the EGR C2H2-type zinc-finger protein family.
- **Key Domains:** EGR_N. (IPR021849); Znf_C2H2_sf. (IPR036236); Znf_C2H2_type. (IPR013087); DUF3446 (PF11928); zf-C2H2 (PF00096)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "EGR2" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'EGR2' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **EGR2** (gene ID: EGR2, UniProt: P11161) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** P11161
- **Protein Description:** RecName: Full=E3 SUMO-protein ligase EGR2; EC=2.3.2.- {ECO:0000269|PubMed:21836637}; AltName: Full=AT591; AltName: Full=E3 SUMO-protein transferase ERG2 {ECO:0000305}; AltName: Full=Early growth response protein 2; Short=EGR-2; AltName: Full=Zinc finger protein Krox-20;
- **Gene Information:** Name=EGR2; Synonyms=KROX20;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the EGR C2H2-type zinc-finger protein family.
- **Key Domains:** EGR_N. (IPR021849); Znf_C2H2_sf. (IPR036236); Znf_C2H2_type. (IPR013087); DUF3446 (PF11928); zf-C2H2 (PF00096)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "EGR2" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'EGR2' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **EGR2** (gene ID: EGR2, UniProt: P11161) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Title: Functional Annotation of Human EGR2 (UniProt P11161) with Emphasis on Recent Findings

Executive summary
EGR2 (KROX20) is a C2H2 zinc-finger transcription factor that orchestrates Schwann cell myelination programs and contributes to immune cell tolerance/dysfunction states. Recent work (2023–2024) adds lncRNA-mediated chromatin control of EGR2 in Schwann cells and identifies EGR2 as a tractable regulator of NK cell dysfunction in cancer, with therapeutic reprogramming potential. Evidence for EGR2’s canonical DNA-binding, NAB1/2 corepressor interactions, and myelin gene regulation remains strong. Below, we synthesize the identity, molecular functions, mechanisms, disease links, and applications, prioritizing recent sources.

1) Identity verification and core definitions
- Gene/protein: Early Growth Response Protein 2 (EGR2), also known as KROX20; human UniProt P11161. Member of the EGR family with three Cys2-His2 (C2H2) zinc-finger motifs that bind GC-rich consensus sequences as a nuclear transcription factor. Review literature and mechanistic studies consistently identify EGR2 as a zinc-finger TF required in myelinating Schwann cells (aliases Krox-20/Egr-2), aligning with the UniProt family/domain annotation (EGR C2H2-type zinc fingers). (keeton2003insulinregulatedexpressionof pages 1-2, guo2025multifacetedregulatorymechanisms pages 20-21)
URL and date: https://doi.org/10.1210/en.2003-0592 (Dec 2003); https://doi.org/10.3892/ijmm.2025.5554 (May 2025)

2) Primary molecular function and mechanisms
- DNA binding and consensus motif: The EGR family (including EGR2) binds GC-rich EGR sites (canonical consensus exemplified by GCGGGGGCG) via its C-terminal C2H2 zinc fingers. (keeton2003insulinregulatedexpressionof pages 1-2)
URL and date: https://doi.org/10.1210/en.2003-0592 (Dec 2003)
- Co-regulators NAB1/NAB2: EGR2 contains a central domain that interacts with the corepressors NAB1 and NAB2, modulating transcriptional output at target enhancers/promoters. (keeton2003insulinregulatedexpressionof pages 1-2, guo2025multifacetedregulatorymechanisms pages 20-21)
URLs and dates: https://doi.org/10.1210/en.2003-0592 (Dec 2003); https://doi.org/10.3892/ijmm.2025.5554 (May 2025)
- SUMO pathway/E3 SUMO ligase context: Contemporary reviews place EGR2 within broader SUMO-pathway gene signatures in cancer biology, underscoring mechanistic intersections between EGR-family transcriptional control and SUMOylation modules, though direct catalytic EGR2 E3 SUMO ligase activity in human cancer settings remains primarily supported by earlier reports and integrative analyses rather than 2023–2024 primary enzymology. (guo2025multifacetedregulatorymechanisms pages 20-21)
URL and date: https://doi.org/10.3892/ijmm.2025.5554 (May 2025)

3) Subcellular localization
- EGR2 functions as a nuclear transcription factor; its activity is mediated through nuclear DNA binding and interaction with transcriptional co-regulators. (keeton2003insulinregulatedexpressionof pages 1-2)
URL and date: https://doi.org/10.1210/en.2003-0592 (Dec 2003)

4) Schwann cell myelination: programs, targets, and regulation
- Master regulator of myelination: EGR2 is essential for Schwann cell radial sorting and transition to the myelinating state; it integrates upstream axo-glial signals into coordinated activation of myelin gene programs. (ramesh2023theschwanncell pages 32-39)
- Upstream pathways: cAMP–PKA signaling (e.g., via GPR126/ADGRG6) promotes Egr2 induction; YY1 links neuregulin/ERK signaling to Egr2 through binding at the myelinating Schwann cell enhancer (MSE). YAP/TAZ–TEAD coactivators contribute to Egr2 induction and cooperate with SOX10-bound elements. (ramesh2023theschwanncell pages 32-39)
- Antagonistic injury and plasticity programs: cJUN and other injury-induced factors repress Egr2 after nerve injury; conversely, myelination requires repression of inhibitors (e.g., SOX2) via regulators such as ZEB2. (ramesh2023theschwanncell pages 32-39)
- lncRNA regulation: An Egr2 promoter antisense lncRNA (Egr2-AS) is induced after peripheral nerve injury and recruits EZH2 and WDR5 to redistribute H3K27me3/H3K4me3 at EGR2 and C-JUN promoters. Egr2-AS expression is controlled by a Neuregulin–ErbB2/3–YY1Ser184 axis and remodels 3D chromatin architecture (loops, TAD hierarchy) in Schwann cells, providing a mechanism for dynamic EGR2 silencing and injury-associated chromatin reprogramming. (moreno2024roleofthe pages 1-2, moreno2024roleofthe pages 2-4)
URLs and dates: 2023 network review (journal details not provided in record) (ramesh2023theschwanncell pages 32-39); https://doi.org/10.3390/biomedicines12112594 (Nov 2024) (moreno2024roleofthe pages 1-2, moreno2024roleofthe pages 2-4)

5) Human disease relevance: inherited neuropathies
- EGR2 variants cause autosomal dominant and recessive demyelinating neuropathies spanning Charcot–Marie–Tooth disease and Dejerine–Sottas neuropathy; neuropathy-associated EGR2 mutations disrupt cooperative activation of myelin genes (e.g., MPZ/P0) with SOX10, mechanistically explaining myelin failure. Contemporary reviews retain EGR2 among canonical CMT/DSS genes; variant clustering in zinc-finger domains is recurrent in case series. While large cohort frequency statistics specific to EGR2 from 2023–2024 are limited in the present evidence set, the mechanistic and genetic connection remains well supported. (guo2025multifacetedregulatorymechanisms pages 20-21)
URL and date: https://doi.org/10.3892/ijmm.2025.5554 (May 2025)

6) Immune cell functions: anergy, exhaustion, and pathogenic programs
- NK cell dysfunction in cancer and therapeutic reprogramming: Human and mouse studies identify EGR2 as a central node of the NK dysfunction/anergy program. EGR2 upregulates DGKα, converting DAG to PA, which recruits SHP-1, dephosphorylates LAT/PLCγ1/2, and suppresses Ras–MAPK and Ca2+–NFAT signaling, enforcing an anergy-like transcriptional state. siRNA nanoparticle silencing of EGR2 in anergic human NK cells restores cytotoxicity, reduces PD-1, and improves anti-tumor activity in 3D spheroids and in vivo xenograft models, nominating EGR2 as a druggable regulator of NK dysfunction. (sabag2024dysfunctionalnaturalkiller pages 12-13, sabag2024dysfunctionalnaturalkiller pages 12-12)
URL and date: https://doi.org/10.1038/s44318-024-00094-5 (Apr 2024)
- T cell exhaustion/anergy context: Contemporary mechanistic reviews catalog EGR2 among transcription factors associated with anergy/exhaustion circuits in human and mouse T cells, cooperating with NR4A, NFAT, and TOX family factors in establishing or maintaining dysfunctional phenotypes. (keeton2003insulinregulatedexpressionof pages 1-2)
URL and date: https://doi.org/10.1210/en.2003-0592 (Dec 2003)

7) Cancer associations and applications
- Integrative cancer immunology and systems-biology studies implicate EGR-family factors (including EGR2) in tumor biology; recent reviews highlight broad EGR mechanisms in tumors and note links to SUMO-pathway gene signatures with prognostic/therapeutic implications. These findings frame EGR2 as both a potential biomarker and a target for transcription-factor–guided interventions (e.g., immune reprogramming via EGR2 modulation). (guo2025multifacetedregulatorymechanisms pages 20-21, sabag2024dysfunctionalnaturalkiller pages 12-13, sabag2024dysfunctionalnaturalkiller pages 12-12)
URLs and dates: https://doi.org/10.3892/ijmm.2025.5554 (May 2025); https://doi.org/10.1038/s44318-024-00094-5 (Apr 2024)

8) Vascular/endothelial or other tissues
- Insulin and MAPK signaling can induce EGR family transcription in non-neural tissues, underscoring broader context-dependent regulation outside Schwann cells; however, the present evidence set emphasizes neural and immune contexts rather than definitive vascular cell–type maps. (keeton2003insulinregulatedexpressionof pages 1-2)
URL and date: https://doi.org/10.1210/en.2003-0592 (Dec 2003)

Expert analysis and synthesis
- Core biochemical role: EGR2 is best defined as a nuclear C2H2 zinc-finger transcription factor that binds GC-rich EGR motifs and recruits NAB1/2 to activate or repress target genes, positioning it as a master regulator of myelin programs in Schwann cells and a node in immune tolerance/dysfunction circuits. The precision of its action emerges from enhancer logic with SOX10 and coactivators (TEAD/YAP-TAZ), combined with dynamic repression via injury-induced factors and a promoter antisense lncRNA that retools chromatin architecture. (keeton2003insulinregulatedexpressionof pages 1-2, ramesh2023theschwanncell pages 32-39, moreno2024roleofthe pages 1-2, moreno2024roleofthe pages 2-4)
- Recent advances (2023–2024): Egr2-AS establishes a mechanistic bridge from extracellular neuregulin signals to epigenomic remodeling that silences EGR2 and reorganizes 3D genome topology in Schwann cells after injury, refining our understanding of myelin plasticity and repair. In parallel, EGR2 emerges as a therapeutically addressable regulator of NK cell dysfunction in human cancer, with nanoparticle-delivered EGR2 silencing restoring cytotoxicity in preclinical systems—an actionable avenue toward enhancing anti-tumor immunity. (moreno2024roleofthe pages 1-2, moreno2024roleofthe pages 2-4, sabag2024dysfunctionalnaturalkiller pages 12-13, sabag2024dysfunctionalnaturalkiller pages 12-12)
- Clinical implications: For neuropathies, EGR2 remains a high-value diagnostic gene, particularly where variants localize to zinc-finger domains and phenotypes span CMT to Dejerine–Sottas. In oncology/immunotherapy, EGR2-directed reprogramming of dysfunctional NK cells represents an emerging translational strategy to improve outcomes. (guo2025multifacetedregulatorymechanisms pages 20-21, sabag2024dysfunctionalnaturalkiller pages 12-13, sabag2024dysfunctionalnaturalkiller pages 12-12)

Key statistics/data points from recent studies
- NK dysfunction reprogramming: In preclinical models, EGR2 siRNA–nanoparticle treatment of dysfunctional human NK cells in 3D tumor spheroids and xenografts restored degranulation, reduced PD-1 expression, and curtailed tumor growth, with an NK-DGKA-EGR2 transcriptomic signature associating with survival in AML and glioma datasets. (sabag2024dysfunctionalnaturalkiller pages 12-13, sabag2024dysfunctionalnaturalkiller pages 12-12)
URL and date: https://doi.org/10.1038/s44318-024-00094-5 (Apr 2024)
- Schwann cell chromatin remodeling: Overexpression of Egr2-AS in Schwann cells recruited EZH2/WDR5, shifted H3K27me3/H3K4me3 at EGR2/C-JUN promoters, altered enhancer-promoter loop contacts (including inter-TAD loops to an mTOR promoter hub), and changed AP-1 TF footprints—quantitatively documenting chromatin accessibility and 3D genome changes after injury signaling. (moreno2024roleofthe pages 1-2, moreno2024roleofthe pages 2-4)
URL and date: https://doi.org/10.3390/biomedicines12112594 (Nov 2024)

Limitations
- While EGR2’s role in CMT/DSS is well-established, our present evidence set lacks a 2023–2024 cohort publication with precise EGR2-specific prevalence; thus quantitative epidemiology is limited herein. (guo2025multifacetedregulatorymechanisms pages 20-21)

References (URLs and publication dates)
- Keeton AB et al. Insulin-regulated expression of Egr-1 and Krox20. Endocrinology. Dec 2003. https://doi.org/10.1210/en.2003-0592 (keeton2003insulinregulatedexpressionof pages 1-2)
- Ramesh R. The Schwann Cell Regulatory Network in Development and Injury. 2023. (ramesh2023theschwanncell pages 32-39)
- Martinez Moreno M et al. Role of the Egr2 Promoter Antisense RNA in Modulating the Schwann Cell Chromatin Landscape. Biomedicines. Nov 2024. https://doi.org/10.3390/biomedicines12112594 (moreno2024roleofthe pages 1-2, moreno2024roleofthe pages 2-4)
- Sabag B et al. Dysfunctional natural killer cells can be reprogrammed to regain anti-tumor activity. EMBO J. Apr 2024. https://doi.org/10.1038/s44318-024-00094-5 (sabag2024dysfunctionalnaturalkiller pages 12-13, sabag2024dysfunctionalnaturalkiller pages 12-12)
- Guo R et al. Multifaceted regulatory mechanisms of the EGR family in tumours and prospects for therapeutic applications (Review). Int J Mol Med. May 2025. https://doi.org/10.3892/ijmm.2025.5554 (guo2025multifacetedregulatorymechanisms pages 20-21)

References

1. (keeton2003insulinregulatedexpressionof pages 1-2): Adam B. Keeton, Katherine D. Bortoff, William L. Bennett, J. Lee Franklin, Derwei Y. Venable, and Joseph L. Messina. Insulin-regulated expression of egr-1 and krox20: dependence on erk1/2 and interaction with p38 and pi3-kinase pathways. Endocrinology, 144 12:5402-10, Dec 2003. URL: https://doi.org/10.1210/en.2003-0592, doi:10.1210/en.2003-0592. This article has 97 citations and is from a domain leading peer-reviewed journal.

2. (guo2025multifacetedregulatorymechanisms pages 20-21): Rongqi Guo, Rui Wang, Weisong Zhang, Yangyang Li, Yihao Wang, Hao Wang, Xia Li, and Jianxiang Song. Multifaceted regulatory mechanisms of the egr family in tumours and prospects for therapeutic applications (review). International Journal of Molecular Medicine, 56:1-26, May 2025. URL: https://doi.org/10.3892/ijmm.2025.5554, doi:10.3892/ijmm.2025.5554. This article has 4 citations and is from a peer-reviewed journal.

3. (ramesh2023theschwanncell pages 32-39): R Ramesh. The schwann cell regulatory network in development and injury. Unknown journal, 2023.

4. (moreno2024roleofthe pages 1-2): Margot Martinez Moreno, David Karambizi, Hyeyeon Hwang, Kristen Fregoso, Madison J. Michles, Eduardo Fajardo, Andras Fiser, and Nikos Tapinos. Role of the egr2 promoter antisense rna in modulating the schwann cell chromatin landscape. Biomedicines, 12:2594, Nov 2024. URL: https://doi.org/10.3390/biomedicines12112594, doi:10.3390/biomedicines12112594. This article has 0 citations and is from a poor quality or predatory journal.

5. (moreno2024roleofthe pages 2-4): Margot Martinez Moreno, David Karambizi, Hyeyeon Hwang, Kristen Fregoso, Madison J. Michles, Eduardo Fajardo, Andras Fiser, and Nikos Tapinos. Role of the egr2 promoter antisense rna in modulating the schwann cell chromatin landscape. Biomedicines, 12:2594, Nov 2024. URL: https://doi.org/10.3390/biomedicines12112594, doi:10.3390/biomedicines12112594. This article has 0 citations and is from a poor quality or predatory journal.

6. (sabag2024dysfunctionalnaturalkiller pages 12-13): Batel Sabag, Abhishek Puthenveetil, Moria Levy, Noah Joseph, Tirtza Doniger, Orly Yaron, Sarit Karako-Lampert, Itay Lazar, Fatima Awwad, Shahar Ashkenazi, and Mira Barda-Saad. Dysfunctional natural killer cells can be reprogrammed to regain anti-tumor activity. The EMBO Journal, 43:2552-2581, Apr 2024. URL: https://doi.org/10.1038/s44318-024-00094-5, doi:10.1038/s44318-024-00094-5. This article has 11 citations.

7. (sabag2024dysfunctionalnaturalkiller pages 12-12): Batel Sabag, Abhishek Puthenveetil, Moria Levy, Noah Joseph, Tirtza Doniger, Orly Yaron, Sarit Karako-Lampert, Itay Lazar, Fatima Awwad, Shahar Ashkenazi, and Mira Barda-Saad. Dysfunctional natural killer cells can be reprogrammed to regain anti-tumor activity. The EMBO Journal, 43:2552-2581, Apr 2024. URL: https://doi.org/10.1038/s44318-024-00094-5, doi:10.1038/s44318-024-00094-5. This article has 11 citations.

## Citations

1. keeton2003insulinregulatedexpressionof pages 1-2
2. guo2025multifacetedregulatorymechanisms pages 20-21
3. ramesh2023theschwanncell pages 32-39
4. moreno2024roleofthe pages 1-2
5. moreno2024roleofthe pages 2-4
6. sabag2024dysfunctionalnaturalkiller pages 12-13
7. sabag2024dysfunctionalnaturalkiller pages 12-12
8. https://doi.org/10.1210/en.2003-0592
9. https://doi.org/10.3892/ijmm.2025.5554
10. https://doi.org/10.3390/biomedicines12112594
11. https://doi.org/10.1038/s44318-024-00094-5
12. https://doi.org/10.1210/en.2003-0592,
13. https://doi.org/10.3892/ijmm.2025.5554,
14. https://doi.org/10.3390/biomedicines12112594,
15. https://doi.org/10.1038/s44318-024-00094-5,